WO1993015732A1 - Traitement du glaucome - Google Patents

Traitement du glaucome Download PDF

Info

Publication number
WO1993015732A1
WO1993015732A1 PCT/US1993/001431 US9301431W WO9315732A1 WO 1993015732 A1 WO1993015732 A1 WO 1993015732A1 US 9301431 W US9301431 W US 9301431W WO 9315732 A1 WO9315732 A1 WO 9315732A1
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
glaucoma
eye
intra
constitutions
Prior art date
Application number
PCT/US1993/001431
Other languages
English (en)
Inventor
William Cash
Georg Mathis
Marc De Gasparo
Original Assignee
Ciba Vision Ag, Hettlingen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Vision Ag, Hettlingen filed Critical Ciba Vision Ag, Hettlingen
Priority to JP5514345A priority Critical patent/JPH07504099A/ja
Priority to EP93906040A priority patent/EP0626846A1/fr
Publication of WO1993015732A1 publication Critical patent/WO1993015732A1/fr
Priority to NO942756A priority patent/NO942756L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole

Definitions

  • glaucoma covers pathological symptoms of the eye that are attributable to elevated intra-ocular pressure. Obstruction of the movement of aqueous humour often causes an increase in intra-ocular pressure. Chronically increased intra-ocular pressure has a damaging effect on the optic nerve and the retina, which can result not only in a restricted field of vision but also in blindness.
  • U.S. Patent No. 5 036 048 describes angio- tensin-II antagonists as being suitable agents for the treatment of glaucoma.
  • the compounds of formula (I) and their salts were also found to have a surprisingly long duration of action when used in the treatment of male albino rats, in which intra-ocular hypertension had been produced, using the glucocorticoid model.
  • the compounds of formula (I) or salts thereof are also distinguished by being extremely well tolerated by the eye, which can be demonstrated in a test model using rabbits' eyes.
  • eye drops comprising the active ingredient in different concentrations are administered to the conjunctival sac of animals of the Himalaya type (pigmented), for example over a period of five days. Ophthalmological and ophthalmopathological examinations revealed no local or systemic intolerances.
  • Another surprising effect is that the compounds of formula (I) and their salts have a vaso-relaxing effect on the eye, both when administered topically and when administered systemically, and can accordingly be used in the treatment of vasospastic constitutions of the eye.
  • the compounds of formula (I) and their salts can be used in the treatment of diabetic retinopathy.
  • the present invention relates to the use of the compounds of formula (I) and their salts in the preparation of pharmaceutical compositions for the treatment of glaucoma, for increas ⁇ ing the movement of (retinal) intra-ocular fluid, being the aqueous humour, for the treatment of vasospastic constitutions of the eye and for the treatment of diabetic retino ⁇ pathy.
  • the present Application relates also to a method of treating glaucoma, increasing the movement of (retinal) intra-ocular fluid, treating vasospastic constitutions of the eye and treating diabetic retinopathy, which method comprises administering to patients requiring such treatment a therapeutically effective amount of a compound of formula (I) or of a pharmaceutically acceptable salt thereof.
  • Compounds (I) and, where appropriate, their tautomers may be in the form of salts. especially pharmaceutically acceptable salts.
  • compounds (I) have, for example, at least one basic centre, they can form acid addition salts.
  • the latter are formed, for example, with strong inorganic acids, such as mineral acids, for example sulfuric acid, a phosphoric acid or a hydrohalic acid, with strong organic carboxylic acids, such as unsubs- tituted or substituted, for example halo-substituted, C 1 -C 4 alkanecarboxylic acids, for example acetic acid, such as saturated or unsaturated dicarboxylic acids, for example oxalic, malonic, succinic, maleic, fumaric, phthalic or terephthalic acid, such as hydroxy- carboxylic acids, for example ascorbic, glycolic, lactic, malic, tartaric or citric acid, such as amino acids, for example aspartic or glutamic acid, or such
  • Corresponding acid addition salts can also be formed with any additional basic centre that may be present.
  • compounds (I), having the acidic 5-tetrazolyl group can form salts with bases.
  • Suitable salts with bases are, for example, metal salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium or magnesium salts, or salts with ammonia or an organic amine, such as morpholine, thio- morpholine, piperidine, pyrrolidine, a mono-, di- or tri-lower alkylamine, for example ethyl-, tert-butyl-, diethyl-, diisopropyl-, triethyl-, tributyl- or dimethyl-propyl-amine, or a mono-, di- or tri-hydroxy-lower alkylamine, for example mono-, di- or tri-ethanolamine.
  • Corresponding internal salts can also be formed.
  • the present Application relates also to pharmaceutical compositions for the treatment of glaucoma, for increasing the movement of (retinal) fluid, for the treatment of vasospastic constitutions of the eye and for the treatment of diabetic retinopathy, comprising a thera- Chamberically effective amount of a compound of formula (I) or of a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable formulation agent suitable for ophthalmic and for systemic use.
  • compositions are advantageously administered topically to the eye, especially in the form of a solution, an ointmen , a gel or a solid insert.
  • Such compositions comprise the active ingredient, for ex _ pie, in a range of from approx ⁇ imately 0.01 to approximately 10.0 % by weight, preferably from approximately 0.5 to approximately 5.0 % by weight.
  • Unit dose forms of the active ingredient comprise, for example, from approximately 0.001 to approximately 5.0 % by weight, especially from approximately 0.05 to approximately 2.0 % by weight, preferably from approximately 0.1 to approximately 1.5 % by weight, more especially from approximately 0.1 to approx- imately 1.0 % by weight, of active ingredient.
  • the dose of the active ingredient may depend on various factors, such as mode of administration, requirement, age and/or individual condition.
  • compositions customary pharmaceutically acceptable excipients or additives known to the person skilled in the art, for example those of the type mentioned below, especially with the addition of isotonising agents, buffers, complexing agents, solubilisers and thickeners.
  • excipients and additives can be found in the PCT Patent Application having the publication number WO 91/15206.
  • Such compositions are prepared in a manner known per se, for example by mixing the active ingredient with the corresponding excipients and/or additives to form corresponding ophthalmic compositions.
  • the active ingredient is preferably administered in the form of eye drops, being dissolved especially in a sterile, aqueous isotonic solution which, if necessary, is buffered to the desired pH value.
  • the invention relates likewise to systemically administrable pharmaceutical compositions that comprise a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient, and to a process for the preparation thereof.
  • compositions are for enteral, such as oral, and also rectal or parenteral administration to warm-blooded animals, the pharmacological active ingredient being comprised on its own or together with customary pharmaceutical excipients.
  • the pharmaceutical compositions comprise, for example, approximately from 0.1 % to 100 %, preferably from approximately 1 % to approximately 60 %, of the active ingredient.
  • Pharmaceutical compositions for enteral or parenteral and also for ocular administration are, for example, compositions in unit dose forms, such as dragdes, tablets, capsules or suppositories, and also ampoules.
  • Those compositions are prepared in a manner known p_er se, for example by means of conventional mixing, granulating, confectioning, dissolving or lyophilising processes.
  • compositions for oral adminis ⁇ tration can be obtained by combining the active ingredient with solid carriers, optionally granulating a resulting mixture and, if desired, processing the mixture or granules, if necessary after the addition of suitable excipients, to form tablets or drag ⁇ e cores.
  • Suitable carriers are especially fillers, such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tri- calcium phosphate or calcium hydrogen phosphate, also binders, such as starch pastes using, for example, corn, wheat, rice or potato starch, gelatin, gum tragacanth, methyl- cellulose and/or polyvinylpyrrolidone, and, if desired, disintegrators, such as the above- mentioned starches, also carboxymethyl starch, cross-linked polyvinylpyrrolidone, agar or alginic acid or a salt thereof, such as sodium alginate.
  • fillers such as sugars, for example lactose, saccharose, mannitol or sorbitol
  • cellulose preparations and/or calcium phosphates for example tri- calcium phosphate or calcium hydrogen phosphate
  • binders such as starch pastes using, for example,
  • Excipients are especially flow conditioners and lubricants, for example silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and or polyethylene glycol.
  • Drag ⁇ e cores are provided with suitable, optionally enteric, coatings, there being used, inter alia, concentrated sugar solutions which may comprise gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, or coating solutions in suitable organic solvents or solvent mixtures, or, for the production of enteric coatings, solutions of suitable cellulose prepar ⁇ ations, such as acetylcellulose phthalate or hydroxypropylmethylcellulose phthalate. Colourings or pigments may be added to the tablets or drag ⁇ e coatings, for example for identification purposes or to indicate different doses of active ingredient.
  • compositions include dry-filled capsules consisting of gelatin, and also soft, sealed capsules consisting of gelatin and a plasticiser, such as glycerol or sorbitol.
  • the dry-filled capsules may contain the active ingredient in the form of granules, for example in admixture with fillers, such as lactose, binders, such as starches, and/or glidants, such as talc or magnesium stearate, and optionally stabilisers.
  • the active ingredient is preferably dissolved or suspended in suitable liquids, such as fatty oils, paraffin oil or liquid polyethylene glycols, to which stabilisers may likewise be added.
  • Suitable rectally administrable pharmaceutical compositions are, for example, suppositories that consist of a combination of the active ingredient and a suppository base.
  • Suitable suppository bases are, for example, natural or synthetic triglycerides, paraffin hydrocarbons, polyethylene glycols and higher alkanols. It is also possible to use gelatin rectal capsules that comprise a combination of the active ingredient and a base material.
  • Suitable base materials are, for example, liquid triglycerides, polyethylene glycols and paraffin hydrocarbons.
  • aqueous solutions of an active ingredient in water-soluble form for example in the form of a water-soluble salt
  • suspensions of the active ingredient such as corresponding oily injection suspensions
  • suitable lipophilic solvents or vehicles such as fatty oils, for example sesame oil, or synthetic fatty acid esters, for example ethyl oleate or triglycerides, or aqueous injection suspensions that comprise viscosity-increasing substances, for example sodium carboxymethylcellulose, sorbitol and/or dextran, and, if desired, also stabilisers.
  • the dose of the active ingredient may depend on various factors, such as the mode of administration, species of warm-blooded animal, age and/or individual condition.
  • the present Application relates also to the use of a compound of formula (I) or a pharma ⁇ ceutically acceptable salt thereof in the preparation of pharmaceutical compositions for the treatment of glaucoma, for increasing the movement of (retinal) intra-ocular fluid, for the treatment of vasospastic constitutions of the eye and for the treatment of diabetic retino ⁇ pathy.
  • a solution comprising 20 mg of active ingredient, for example (S)-N-( 1 -carboxy-2-methylprop- 1 -y I)-N-pentanoyl-N- [2' -( 1 H-tetrazol-5-yl)- biphenyl-4-ylmethyl]-amine, can be made up as follows:
  • the constituents are introduced into water and dissolved.
  • a compound of formula (I) or a pharmaceutically acceptable salt thereof can be processed in an analogous manner, for example as described in the above Examples.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne l'utilisation des composés de la formule (I), dans laquelle X représente (Ia) ou (Ib), le groupe carboxy étant lié directement au cycle cyclopentyle lorsque X = (Ia), ainsi que leurs sels dans la préparation de compositions pharmaceutiques utilisées dans le traitement du glaucome, afin d'accroître le mouvement de fluide intra-oculaire (rétinien), dans le traitement de constitutions angiospastiques de l'÷il, et dans le traitement de la rétinopathie diabétique, ainsi que des compositions ophtalmiques correspondantes.
PCT/US1993/001431 1992-02-17 1993-02-17 Traitement du glaucome WO1993015732A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP5514345A JPH07504099A (ja) 1992-02-17 1993-02-17 緑内障の治療
EP93906040A EP0626846A1 (fr) 1992-02-17 1993-02-17 Traitement du glaucome
NO942756A NO942756L (no) 1992-02-17 1994-07-22 Behandling av glaucoma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH45992 1992-02-17
CH459/92-4 1992-02-17

Publications (1)

Publication Number Publication Date
WO1993015732A1 true WO1993015732A1 (fr) 1993-08-19

Family

ID=4187501

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/001431 WO1993015732A1 (fr) 1992-02-17 1993-02-17 Traitement du glaucome

Country Status (8)

Country Link
EP (1) EP0626846A1 (fr)
JP (1) JPH07504099A (fr)
AU (1) AU3722493A (fr)
CA (1) CA2128324A1 (fr)
IL (1) IL104755A0 (fr)
NO (1) NO942756L (fr)
WO (1) WO1993015732A1 (fr)
ZA (1) ZA931063B (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995021609A1 (fr) * 1994-02-08 1995-08-17 Ciba-Geigy Ag Antagonistes de l'angiotensine ii destines au traitement du glaucome normotensif
WO1995024901A1 (fr) * 1994-03-17 1995-09-21 Ciba-Geigy Ag Traitement de la nephropathie diabetique a l'aide de valsartan
WO2000010605A2 (fr) * 1998-08-20 2000-03-02 Senju Pharmaceutical Co., Ltd. Prophylaxie ou remedes pour la perturbation circulatoire de l'oeil
WO2000066161A1 (fr) * 1999-04-28 2000-11-09 Takeda Chemical Industries, Ltd. Preventifs / remedes / inhibiteurs de progression pour retinopathie simplex ou retinopathie preproliferante
US6294197B1 (en) 1996-06-27 2001-09-25 Novartis Ag Solid oral dosage forms of valsartan
US6649625B2 (en) 1998-08-17 2003-11-18 Senju Pharmaceutical Co., Ltd. Agent for prophylaxis and treatment of glaucoma
EP1488789A1 (fr) * 2002-03-08 2004-12-22 Sankyo Company, Limited Gouttes ophtalmologiques contenant un derive de tetrazole
WO2006058592A1 (fr) * 2004-12-01 2006-06-08 Merck Patent Gmbh Nouveaux inhibiteurs specifiques de la caspase-10

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036048A (en) * 1986-03-07 1991-07-30 Schering Corporation Angiotensin II receptor blockers as antiglaucoma agents
EP0443983A1 (fr) * 1990-02-19 1991-08-28 Ciba-Geigy Ag Composés acylés
WO1991014679A1 (fr) * 1990-03-20 1991-10-03 Sanofi Derives heterocycliques n-substitues, leur preparation, les compostions pharmaceutiques en contenant
FR2672891A1 (fr) * 1991-02-20 1992-08-21 Synthelabo Derives de 3-pyrazolones, leur preparation et leur application en therapeutique.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036048A (en) * 1986-03-07 1991-07-30 Schering Corporation Angiotensin II receptor blockers as antiglaucoma agents
EP0443983A1 (fr) * 1990-02-19 1991-08-28 Ciba-Geigy Ag Composés acylés
WO1991014679A1 (fr) * 1990-03-20 1991-10-03 Sanofi Derives heterocycliques n-substitues, leur preparation, les compostions pharmaceutiques en contenant
FR2672891A1 (fr) * 1991-02-20 1992-08-21 Synthelabo Derives de 3-pyrazolones, leur preparation et leur application en therapeutique.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CARDIOVASCULAR DRUG REVIEWS vol. 9, no. 4, 1991, pages 317 - 339 P.C. WONG ET AL. 'LOSARTAN (DUP 753), AN ORALLY ACTIVE NONPEPTIDE ANGIOTENSIN II RECEPTOR ANTAGONIST' *
THE FASEB JOURNAL vol. 5, no. 5, 1991, page A1218 S. WILSON ET AL. 'THE OCULAR HYPOTENSIVE EFFECT OF DUP 753, A NON-PEPTIDE ANGIOTENSIN II ANTAGONIST' *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889020A (en) * 1994-02-08 1999-03-30 Ciba Vision Corporation Treatment of normotensive glaucoma with angiotensin II antagonists
WO1995021609A1 (fr) * 1994-02-08 1995-08-17 Ciba-Geigy Ag Antagonistes de l'angiotensine ii destines au traitement du glaucome normotensif
WO1995024901A1 (fr) * 1994-03-17 1995-09-21 Ciba-Geigy Ag Traitement de la nephropathie diabetique a l'aide de valsartan
US6858228B2 (en) 1996-06-27 2005-02-22 Novartis Ag Solid oral dosage forms of valsartan
US6294197B1 (en) 1996-06-27 2001-09-25 Novartis Ag Solid oral dosage forms of valsartan
US6485745B1 (en) 1996-06-27 2002-11-26 Novartis Ag Solid oral dosage forms of valsartan
US6649625B2 (en) 1998-08-17 2003-11-18 Senju Pharmaceutical Co., Ltd. Agent for prophylaxis and treatment of glaucoma
US6673812B1 (en) 1998-08-17 2004-01-06 Senju Pharmaceutical Co., Ltd. Preventives/remedies for glaucoma
WO2000010605A3 (fr) * 1998-08-20 2000-06-02 Senju Pharma Co Prophylaxie ou remedes pour la perturbation circulatoire de l'oeil
WO2000010605A2 (fr) * 1998-08-20 2000-03-02 Senju Pharmaceutical Co., Ltd. Prophylaxie ou remedes pour la perturbation circulatoire de l'oeil
WO2000066161A1 (fr) * 1999-04-28 2000-11-09 Takeda Chemical Industries, Ltd. Preventifs / remedes / inhibiteurs de progression pour retinopathie simplex ou retinopathie preproliferante
US7064141B1 (en) 1999-04-28 2006-06-20 Takeda Pharmaceutical Company Limited Method for preventing, treating or inhibiting development of simple retinopathy and preproliferative retinopathy
CZ301913B6 (cs) * 1999-04-28 2010-07-28 Takeda Pharmaceutical Company Limited Farmaceutický prípravek pro predcházení, lécení nebo inhibování vývoje jednoduché retinopatie nebo predproliferacní retinopatie
EP1488789A1 (fr) * 2002-03-08 2004-12-22 Sankyo Company, Limited Gouttes ophtalmologiques contenant un derive de tetrazole
EP1488789A4 (fr) * 2002-03-08 2010-11-03 Sankyo Co Gouttes ophtalmologiques contenant un derive de tetrazole
WO2006058592A1 (fr) * 2004-12-01 2006-06-08 Merck Patent Gmbh Nouveaux inhibiteurs specifiques de la caspase-10
US7829721B2 (en) 2004-12-01 2010-11-09 Merck Patent Gmbh Specific caspase-10 inhibitors

Also Published As

Publication number Publication date
EP0626846A1 (fr) 1994-12-07
AU3722493A (en) 1993-09-03
CA2128324A1 (fr) 1993-08-19
NO942756D0 (no) 1994-07-22
JPH07504099A (ja) 1995-05-11
IL104755A0 (en) 1993-06-10
NO942756L (no) 1994-07-22
ZA931063B (en) 1993-09-23

Similar Documents

Publication Publication Date Title
EP0326915B1 (fr) Composition thérapeutique à usage local pour traiter les maladies inflammatoires
EP1884234B1 (fr) Agent prophylactique ou therapeutique pour un trouble de la cornee et de la conjonctive
US5889020A (en) Treatment of normotensive glaucoma with angiotensin II antagonists
JPH0696521B2 (ja) 眼局所投与用眼圧降下剤
US5438060A (en) Method of reducing elevated intraocular pressure
US20080161389A1 (en) Method of treating ocular hypertension and intestinal disorders by using dianhydrohexite mononitrate derivatives
WO1993015732A1 (fr) Traitement du glaucome
WO1995024901A1 (fr) Traitement de la nephropathie diabetique a l'aide de valsartan
KR100192745B1 (ko) 안질환 치료용 5-메틸-이속사졸-4-카르복실산아닐리드 및 2-하이드록시에틸리덴-시아노아세트산아닐리드
JPS6225645B2 (fr)
US6294544B1 (en) Peripheral circulation improvers for ophthalmic tissues containing dihydropyridines
SK280537B6 (sk) Použitie derivátov xantínu na výrobu liečiv na oše
ES2279100T3 (es) Derivados de quinolina.
JP3662944B2 (ja) 点鼻剤
US5308849A (en) Method of reducing elevated intraocular pressure
AU2002328856A1 (en) Benzo (G) quinoline derivatives for treating glaucoma and myopia
WO1993015717A1 (fr) Compositions de traitement du glaucome
JPH10500130A (ja) テラゾシンを含有する緑内障治療用医薬組成物
JPH08231400A (ja) イフェンプロジルを必須成分とする眼圧降下剤
WO2006053150B1 (fr) Compositions pharmaceutiques pour application topique, pour le traitement de la degenerescence maculaire liee a l'age et de l'hypertension oculaire
EP1757601B1 (fr) Dérivés de quinoline et leur utilisation en glaucome et myopie
US5428030A (en) Method of reducing elevated intraocular pressure
JPH0778022B2 (ja) 緑内障治療剤
JPH03128370A (ja) 新規なスルフォンアミド
JP2000319181A (ja) ブドウ膜炎治療剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR CA CZ FI HU JP KP KR LK MG MN MW NO NZ PL RO RU SD SK UA US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)

Free format text: PL

WWE Wipo information: entry into national phase

Ref document number: 1993906040

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2128324

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 249706

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 1994 290746

Country of ref document: US

Date of ref document: 19940812

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1993906040

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1993906040

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1993906040

Country of ref document: EP